Detalles de la búsqueda
1.
Third Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer: Summary of the results of a questionnaire survey of oncologists and diabetologists-Secondary publication.
Cancer Sci
; 115(2): 672-681, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38184804
2.
Novel endoscopic duodenal observation protocol based on Seven Pictures Rule for detecting duodenal neoplasms during esophagogastroduodenoscopy: Prospective observational study.
Dig Endosc
; 36(2): 154-161, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37171696
3.
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
Esophagus
; 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38607538
4.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Br J Cancer
; 129(6): 1032-1039, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37532830
5.
The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer.
Future Oncol
; 19(17): 1165-1174, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37458152
6.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Lancet
; 398(10302): 759-771, 2021 08 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34454674
7.
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial.
BMC Cancer
; 22(1): 711, 2022 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35765021
8.
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Jpn J Clin Oncol
; 52(7): 725-734, 2022 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35470391
9.
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Int J Clin Oncol
; 27(9): 1450-1458, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861943
10.
Guidewire-assisted over-the-scope clip delivery method into the distal intestine: a case series.
Minim Invasive Ther Allied Technol
; 31(2): 246-251, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32644856
11.
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Esophagus
; 19(4): 683-692, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35668304
12.
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
Cancer Sci
; 112(1): 314-322, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33075166
13.
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Oncologist
; 26(7): e1125-e1132, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33977607
14.
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
Invest New Drugs
; 39(6): 1649-1655, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019214
15.
Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Chemotherapy
; 66(3): 58-64, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34284397
16.
Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer.
Int J Clin Oncol
; 26(11): 2025-2028, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34476649
17.
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
Br J Cancer
; 123(10): 1490-1495, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32863385
18.
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Oncologist
; 25(12): e1855-e1863, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32666647
19.
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
BMC Cancer
; 20(1): 1116, 2020 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33203393
20.
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
BMC Cancer
; 20(1): 687, 2020 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32703200